2024 Annual Conference | April 17-19, 2024 | Salt Palace Convention Center | Salt Lake City, Utah, USA
Meet our 2024 Conference Chairs
Angela Lamarca, MD, PhD, MSc
Madrid, Spain
Angela Lamarca, MD, PhD, MSc
Dr. Angela Lamarca is a medical oncologist who specializes in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumors (NETs). She completed her training in Medical Oncology at the Hospital Universitario La Paz, Madrid. She moved to The Christie NHS Foundation Trust in 2013, where she completed a fellowship programme in HPB and NETs.
She was awarded an American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award in 2017 and in 2018, she was appointed as a Consultant in Medical Oncology at The Christie where she continues her Clinical and Translational Research career in HPB and NETs. Her aim is to achieve a better understanding of pancreatic, biliary tract cancer, and NET malignancies and to identify new treatment strategies for improving patients’ outcomes.
Mitesh J. Borad, MD
Scottsdale, Arizona, USA
Mitesh J. Borad, MD
Dr. Borad received his MD from Rutgers New Jersey Medical School, completed internal medicine training at Cedars-Sinai, medical oncology training at Tulane University, and was a Genomics Medicine and Drug Development Scholar at TGen under the tutelage of Dr. Daniel Von Hoff.
He is a Professor of Medicine, Program Leader for the Gene and Virus Therapy Program, and Director of the Precision Cancer Therapeutics Program at Mayo Clinic. He also serves on the NIH Drug Discovery and Pharmacology (DMP) Study Section as a Standing Member, NIH Hepatobiliary Cancer Task Force, and Board Member of the International Cholangiocarcinoma Research Network (ICRN). His research is focused on the development of novel therapeutics in the liver, biliary and pancreatic cancers by leveraging Next-gen whole genome sequencing approaches, as well as the application of emerging areas, such as the use of recombinant viruses with oncolytic/immunotherapeutic properties.
Do-Youn Oh, MD, PhD
Seoul, Korea
Do-Youn Oh, MD, PhD
Dr. Do-Youn Oh graduated from Seoul National University College of Medicine, and had residency training in Internal Medicine, and fellowship of Hematology/Medical Oncology training in Seoul National University Hospital. She earned her Ph.D Degree in the Department of Internal Medicine, Seoul National University College of Medicine and since 2006, she has been working as a Professor in Seoul National University Hospital.
Her main research interest is gastric cancer, pancreatic cancer and biliary tract cancer with particular interest in translational research and early drug development. She is involved in memberships in the medical society, including Korean Cancer Association, Korean Association of Clinical Oncology, Korean Cancer Study Group, American Society of Clinical Oncology and American Association for Cancer Research.
Basic Science Chairs
Sumera I Ilyas, MBBS
Rochester, Minnesota, USA
Sumera I. Ilyas, MBBS
Sumera I. Ilyas, MBBS, is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and Science. She is a physician-scientist who underwent training in internal medicine at the University of Pittsburgh Medical Center and subsequently completed Gastroenterology and Transplant Hepatology fellowships at the Mayo Clinic, Rochester. Her academic focus is hepatobiliary neoplasia. She is the director of the Mayo Clinic Hepatobiliary Neoplasia Clinic. She has an NIH-funded laboratory program focused on the immunobiology of cholangiocarcinoma and the development of combination immune-directed therapies for treating cholangiocarcinoma.
Daniela Sia, PhD
New York City, New York, USA
Daniela Sia, PhD
Daniela Sia, PhD, is an Assistant Professor in the Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai in New York (US). Dr. Sia is a cancer biologist with a long-standing interest in understanding the molecular basis driving hepatobiliary cancers and translating this information into more effective therapeutic strategies. During her scientific career, Dr. Sia has contributed to elucidating the genomic landscape of cholangiocarcinoma, both intrahepatic and extrahepatic, and established the first immunogenomic classification of hepatocellular carcinoma. Furthermore, she identified a novel targetable FGFR2 fusion protein, FGFR2-PPHLN1, in ~15% of intrahepatic CCA. The current goal of the Sia laboratory is to develop new treatment paradigms for clinically relevant molecular subsets of cholangiocarcinoma using genomic analyses and patient-derived and animal models.